Als-Con-201 Exam Preparation Material | Salesforce Certified Agentforce Life Sciences Consultant

Explanation:
Option C is correct because Salesforce Life Sciences Cloud supports manual territory alignment for affiliated accounts. Salesforce Help for Territory Alignment for Affiliated Accounts states that a user’s territory determines which accounts they can view and manage, and that users can manually align an affiliated account to their territory. The broader Affiliations documentation also explains that affiliation alignment rules can automatically align affiliated accounts, but the scenario specifically asks for manual alignment by field users when needed.
The correct Admin Console setting is therefore the one that enables users to align affiliated accounts to the user’s territory. This setting allows reps working with complex HCO/HCP affiliation networks to bring relevant affiliated accounts into their current territory alignment when the relationship is valid for their business process.
Option A is not the best answer because the requirement is not to align accounts outside the user’s territory. It is to let users align affiliated accounts to their own current territory.
Option B is also incorrect because searching for accounts outside the user’s territory only affects discoverability. It does not grant the ability to perform the actual affiliated-account alignment. Therefore, the consultant should enable “Enable users to align affiliated accounts to the user’s territory” in Account Management > Affiliation.

Explanation:
Data Use Purpose is the correct answer. In Salesforce Life Sciences Cloud Consent Management, a Communication Subscription represents a specific subscription, such as a newsletter, and the consent model must also connect that subscription to the business purpose and relevant Life Sciences product. Salesforce’s Life Sciences Help documentation specifically describes creating a Data Use Purpose record to associate a Life Sciences Marketable Product with a Communication Subscription. That directly matches the scenario: “Immunology Monthly” is the Communication Subscription, and “Immunexis” is the product record that must be linked for consent capture.
Engagement Channel Type is not correct because it represents the channel through which the HCP can be contacted, such as email, SMS, or other communication methods. It defines the communication channel, not the relationship between a subscription and a marketable product. Communication Subscription Consent is also not correct because it represents an individual customer’s or HCP’s consent preference for a subscription. In other words, that record is created or updated when the HCP opts in or opts out; it is not the setup record used to link the newsletter subscription to the product. Salesforce’s Life Sciences standard object documentation also describes Communication Subscription Consent as representing a customer’s consent to a communication subscription, reinforcing that it stores the HCP’s consent outcome rather than the product-subscription configuration.

Explanation:
Option C is correct because Medical Insight upvotes are handled through the UserReaction object and related out-of-the-box logic. Salesforce’s Life Sciences Cloud Developer Guide states that UserReaction represents a user’s reaction to a medical insight, such as an upvote or downvote, and that these reactions are used to identify trending insights. This directly supports the scenario because the problem involves duplicate upvotes and the inability to see total upvote counts on Medical Insight records.
Salesforce’s MedicalInsight object documentation also references fields related to ranking and upvotes, including a default rank determined based on linked insights and their upvotes. This confirms that upvote behavior is part of the standard Medical Insights data model rather than something that should be rebuilt manually.
Option A is not the best answer because MedicalInsightValidationHandler sounds focused on validating Medical Insight records generally, not specifically managing user reactions, duplicate reactions, or upvote counts.
Option B is also not preferred because custom validation rules and a new roll-up summary field would duplicate behavior that Salesforce provides through the Medical Insights user-reaction framework. The requirement asks for the out-of-the-box configuration, so the consultant should activate the UserReactionMedicalInsightHandler to manage upvote reactions consistently and support the total-count behavior.

Explanation:
The correct answer is A because Salesforce Life Sciences Field Email allows field users to add colleagues as CC recipients. Salesforce Help for customizing and sending emails in Life Sciences Cloud states that users can send emails to healthcare professionals and healthcare organizations from their workflow, select an email template, and add colleagues as CC recipients.
This distinction matters for compliance. In Life Sciences engagement, HCPs and HCOs are the intended external recipients of approved email communications. The CC field is not intended as a free-form way to add additional HCPs. Instead, CC is used for internal collaboration or visibility, such as copying a colleague involved in the account, territory, or follow-up process. This helps keep HCP communications controlled, trackable, and aligned with approved email workflows.
Option B is incorrect because it suggests both HCPs and colleagues can be CC’d. Although emails are sent to HCPs or HCOs, Salesforce’s documented CC behavior specifically references colleagues as CC recipients.
Option C is also incorrect because HCPs are the primary external recipients, not the users who should be copied in the CC field. Therefore, when sending email from the Agentforce Life Sciences mobile app, field sales reps can CC colleagues.

Explanation:
Option C is correct because the requirement is strict enforcement. Salesforce Help for Sample Limit Template types states that when the enforcement type is Error, distributions are blocked after limits are met. This directly matches the legal requirement in the question: the field sales rep must be prevented from submitting the visit when the disbursement quantity exceeds the allowed limit.
A controlled substance requires a hard compliance stop rather than a soft business warning. Setting the Limit Enforcement Type to Error ensures that the rep receives an error message and must correct the sample quantity before continuing. This protects the company from noncompliant disbursements and supports controlled sampling governance.
Option A is incorrect because Warning is a soft-limit behavior. A warning may alert the rep that the limit has been exceeded, but it allows the rep to proceed. That does not meet the requirement to strictly prevent the transaction.
Option B is also not the best answer because “Block” is not the documented Limit Enforcement Type in the sample-limit template options shown in Salesforce’s Life Sciences sample limit resources. The documented strict enforcement behavior is Error. Therefore, for controlled substances or any legally required hard stop, the consultant should configure the Sample Limit Template with Limit Enforcement Type set to Error.